September 28, 2016 12:24 AM ET

Biotechnology

Company Overview of Regen BioPharma Inc.

Company Overview

Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It intends to provide various products, including HemaXellerate I, a cellular therapy designed to heal damaged bone marrows; HemaXellerate II, a donor endothelial cell based therapeutic product; dCellVax, a gene silenced dendritic cell immunotherapy for the treatment of breast cancer; and NR2F6, a nuclear receptor cell line. The company was founded in 2012 and is based in La Mesa, California. Regen BioPharma, Inc. is a subsidiary of Bio-Matrix Scientific Group, Inc.

4700 Spring Street

Suite 304

La Mesa, CA 91942

United States

Founded in 2012

Phone:

619-702-1404

Fax:

619-330-2328

Key Executives for Regen BioPharma Inc.

Chairman, Chief Executive Officer, Principal Accounting Officer, Treasurer, Secretary, Chairman of Bio-Matrix Scientific Group and Chief Executive Officer of Bio-Matrix Scientific Group
Age: 55
Total Annual Compensation: $210.0K
Chief Financial Officer and Director
Age: 53
Total Annual Compensation: $101.3K
Senior Research Consultant
Age: 40
Total Annual Compensation: $120.0K
Compensation as of Fiscal Year 2015.

Regen BioPharma Inc. Key Developments

Regen BioPharma Inc. Announces the Completion of Experiments Demonstrating Immunological Effects of Novel NR2F6 Small Molecule Modulators

Regen BioPharma Inc. announced completion of experiments demonstrating immunological effects of its novel NR2F6 small molecule modulators. These experiments were conducted in collaboration with Dr. Xiaojing Ma, Professor of Microbiology and Immunology at Weill Cornell Medical College. The experiments revealed that administration of Regen's proprietary compounds RG-NA01, RG-NI01 and RG-NI02 prevented cells of the immune system from producing the inflammatory factors interleukin-2, interferon-gamma, tumor necrosis factor-alpha and, importantly, interleukin-17a. These factors are critically involved in the immune response found in autoimmune diseases such as rheumatoid arthritis and psoriasis. The company is currently developing small molecule drugs that target NR2F6 and either inhibit production of these factors or, in other cases, stimulate their production. The goal is to have a series of compounds that can modulate the immune system up or down. Regen has recently filed a composition of matter patent application covering these novel NR2F6 small molecule modulators. NR2F6 is a molecular switch which controls genes associated with the immune response.

Regen BioPharma Inc. Announces Small Molecule Drug Screening Program Uncovers Activators of NR2F6

Regen BioPharma Inc. announced identification of small molecules that activate the company's newly identified immune checkpoint NR2F6. This is the first of a series of steps in developing small molecules which the company plans to use as a basis for creating an oral drug that may have potent anti-inflammatory properties. Previously, the company reported that suppressing NR2F6 leads to immune cell activation, including production of the immune-stimulatory cytokines IL-18, IL-17 and IL-2. Thus, activating NR2F6 will likely lead to immune suppression. Given the difficult nature of the NR2F6 target, Regen is excited that using very stringent parameters, the company has been able to identify molecules that not only bind and activate it but also have structural properties making them excellent starting points for drug development. Regen is also optimistic the company will identify inhibitors of NR2F6 in the coming months." NR2F6 is a molecular switch known as a "orphan nuclear receptor" which controls genes associated with the immune response. Regen has filed numerous patent applications covering means of manipulating NR2F6 in oncology and immunology.

Regen Biopharma Inc. Receives Preliminary Clinical Data from Pan Am Cancer Center

Regen BioPharma Inc. announced that the Pan Am Cancer Treatment Center in Tijuana, Mexico, which has a non-exclusive license to test HemaXellerate in a first-in-human proof of concept study, presented interim clinical data on their first 5 patients. Beginning in March 2016, 5 patients with chemotherapy-induced bone marrow suppression were treated with HemaXellerate and initial 1 month follow up data were provided. The primary endpoint of the study is safety and the secondary endpoint is effectiveness. Regarding safety, none of the 5 patients had any adverse events. In other words, all of the patients tolerated HemaXellerate with no side-effects. Effectiveness was measured by taking blood tests of the patients 1 month post-HemaXellerate treatment and measuring the levels of blood cells, particularly immune cells, circulating in their blood. At 1 month post-HemaXellerate treatment, 2 patients (40%) had a dramatic increase in their circulating white blood cells to levels even above the normal range and 2 other patients had their white blood cells return to the normal range.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
July 1, 2016
--
Private Placement
March 22, 2016
--
Private Placement
February 22, 2016
--
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Regen BioPharma Inc., please visit www.regenbiopharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.